Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
99mTc(CO)3BPS-imidazole-EUK
- Development stage
- Preclinical
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
**99mTc(CO)3BPS-imidazole-EUK** is an experimental **PSMA-targeted radiopharmaceutical imaging agent** for prostate cancer. It consists of a technetium-99m tricarbonyl complex coordinated by a bathophenanthroline disulfonate and imidazole-based chelation system attached to the **Glu-Urea-Lys** PSMA-binding pharmacophore. The agent is designed to bind **prostate-specific membrane antigen** on prostate cancer cells and enable nuclear imaging, with reported preclinical binding affinity in LNCaP cells, intracellular uptake, in vitro stability, and mouse biodistribution showing lower kidney uptake than a comparator 99mTc-HYNIC-PSMA tracer. Based on the cited publication, it appears to be an academic-stage preclinical imaging candidate rather than a commercial product, with potential future adaptation of the same chelation concept to rhenium-labeled diagnostic or therapeutic applications.
- Other names
- 99mTc-tricarbonyl-BPS-imidazole-EUK99mTc(CO)3BPS-imidazole-EUK-pentanoic acid
02
Targets
PSMA (Prostate-specific membrane antigen)
Beyond the preview
Go deeper on 99mTc(CO)3BPS-imidazole-EUK.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 99mTc(CO)3BPS-imidazole-EUK.